Intelligence / Healthtech / New Clinical Trials / Hansoh BioMedical R&D Company
Hansoh BioMedical R&D Company
23 Oct 2026: Trial registered · A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 23 Oct 2026
- Title
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07892625
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Hansoh BioMedical R&D Company
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Hansoh BioMedical R&D Company in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.